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Introduction
Sjögren’s syndrome (SS) is a chronic autoimmune disorder of the exocrine glands with 
associated lymphocytic infiltrates in the affected glands. Involvement of the salivary glands 
results in progressive dryness of the mouth, difficulties with chewing, swallowing and 
speech, reduced oral clearance and a shift in oral flora1. As a result of the reduced saliva 
production, patients with SS are likely to have progressive caries and erosion of the teeth, 
and are prone to develop oral infections2. SS has a large impact on health-related quality 
of life (HR-QoL)3 and the oral condition contributes to this4,5. E.g., early loss of teeth 
results in a need of treatment with (partial) dentures, but patients with SS often experience 
functional problems and pain when wearing (partial) dentures because of the dry, sensitive 
oral mucosa. 
Dental implants to retain prostheses are known to improve oral function in edentulous 
healthy subjects6-10. Dental implants can also be used in dentate patients as support for 
crowns or bridges to replace missing teeth. Implant survival rates are up to 98% with 10 
years follow-up8-12. 
Currently, systemic conditions and their therapy, e.g., rheumatoid arthritis (RA), systemic 
lupus erythematosus (SLE), osteoporosis and corticosteroid therapy, are no longer 
considered as risk factors for successful osseointegration of the implants13,14. Despite the 
severe oral complaints, limited evidence is yet available for applying dental implants in 
SS patients. The available support for using dental implants in SS patients is mainly from 
case-reports and small case-series15-19. While most reports show favorable results, one small 
study showed that marginal peri-implant bone loss and bleeding was higher in secondary 
SS (sSS) patients compared with patients with RA without sSS19. Therefore, the aim of 
this retrospective study was to assess clinical outcome of dental implant therapy in our 
cohort of well-classified SS patients. Results were compared to data from matched healthy 
controls obtained from other dental implant studies at our department.
Abstract 
Background
Limited evidence is yet available for applying dental implants in SS patients.
Purpose
To retrospectively assess clinical outcome of dental implant therapy in a cohort of well-
classified patients with Sjögren’s syndrome (SS).
Materials and Methods
All SS patients attending the University Medical Center Groningen for follow-up (n=406) 
were asked whether they had dental implants. In SS patients with implants peri-implant 
health and implant survival was recorded and compared with data from matched healthy 
controls. Patients’ symptoms, health-related quality of life, oral functioning and satisfaction 
were assessed using validated questionnaires. 
Results
Of the responding SS patients (n= 335), 21% was provided with dental implants. In 50 SS 
patients peri-implant health was good with minor marginal bone loss and was comparable 
to those of healthy controls. Implant survival was 97% (median follow-up 46 months (IQR 
26-73) and patients’ satisfaction was high in most SS patients. Peri-implantitis was observed 
in 14% of the SS patients. Oral functioning correlated negatively with dryness, patients’ 
satisfaction and chewing ability in SS patients. 
Conclusions
Implant therapy is common in our cohort of SS patients. Considering the good peri-
implant health, limited prevalence of peri-implantitis, high implant survival and patients’ 
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Peri-implant mucositis and peri-implantitis
Peri-implant mucositis and peri-implantitis were defined according to the criteria proposed 
by Linde & Meyle30. Acceptable bone loss was set at 1.0 mm the first year and not 
exceeding further annual loss of 0.2 mm31,32 combined with a threshold of detectable bone 
loss of 1.0 mm according to Sanz et al.33 In patients without previous radiographic records, 
a threshold vertical distance of 2 mm from the expected marginal bone level following 
remodelling post-implant placement was applied33 .
Questionnaires
All patients completed a set of validated questionnaires regarding their Sjögren-related 
symptoms, HR-QoL, oral functioning and patients’ satisfaction with the prosthetic device. 
The European League Against Rheumatism Sjögren’s Syndrome Patient Reported Index 
(ESSPRI), a patient administered questionnaire, was used to assess patients’ symptoms34. 
ESSPRI total score is the mean of three sub scores: dryness, fatigue and pain, 0 being no 
symptoms, 10 being the worst possible symptoms. Oral dryness specifically was assessed 
using the sub score for oral dryness that was part of the early version of ESSPRI.
HR-QoL was assessed using the Short Form-36 (SF-36)35. The SF-36 is a questionnaire 
consisting of 36 items, with eight scales assessing two dimensions, viz. physical and mental 
health functioning. Scales and summary scores vary from 0 to 100, with 0 being the worst 
possible health status and 100 representing the best possible health status. 
Social impact of oral disorders on well being was assessed using the short version of the 
Oral Health Impact Profile (OHIP14) 36. OHIP 14 consists of 14 items, with a 5-point scale 
from ‘very often’ (score of 4) to ‘never’ (score of 0). Total score ranged from 0-56. 
Subjective chewing ability was assessed using a nine-item questionnaire on which patients 
could rate their ability to chew different kinds of food on a three-point scale7 from 0 
(good) to 2 (bad). Total score ranged from 0-18.
Overall satisfaction with the implant-retained prosthetic device (e.g., crown or prosthesis) 
was expressed on a 10-point rating scale (0– 10); ‘‘0’’ being completely dissatisfied and ‘‘10’’ 
being completely satisfied. 
Statistical analysis
Data were analyzed using IBM SPSS Statistics 22 (SPSS, Chicago, IL, USA). Results were 
expressed as mean ± SD or median (interquartile range; IQR) for normally distributed and 
non-normally distributed data, respectively. Independent samples t test, Mann-Whitney 
U test, and Chi-Square or Fisher’s exact test were used to compare differences in patient 
characteristics between subgroups. Wilcoxon signed rank test and McNemar test were 
used to compare differences in clinical outcome of dental implant therapy between SS 
patients and matched healthy controls. Correlations between questionnaires were analyzed 




All patients with SS (n=406) attending the Department of Rheumatology and Clinical 
Immunology and the Department of Oral and Maxillofacial Surgery of the University 
Medical Center Groningen (UMCG) for standardized routine follow-up in a multidisciplinary 
setting were sent a questionnaire by regular mail regarding their dental status and whether 
or not they had dental implants inserted. All patients were over 18 years of age and were 
classified according to the revised American European Consensus Group criteria for 
primary SS (pSS) or sSS20. All patients who reported to have been treated with dental 
implants were invited by a prosthodontist (AK) for assessing peri-implant health at their 
next scheduled follow-up visit between February 2012 and September 2013. Implant 
survival was recorded from patient recordings and by patient interview. 
Data from previous studies8,9,11,21-27 was used to randomly select healthy controls that 
matched our SS patients with regard to sex, age, position and follow-up of the implants and 
number of implants and implant system used.
The study was extinct of ethical approval according to the local institutional review board 
(Medisch Ethische Toetsingscommissie of the UMCG, the Netherlands, letter M11.110548). 
Peri-implant indices
During the next follow-up visit, clinical screening was performed to assess peri-implant 
mucosal health. Peri-implant indices included plaque index and bleeding index28, gingival 
index29, calculus score and probing depth. Probing depth was measured at four sites of 
each implant (mesially, labially, distally and lingually) using a periodontal probe (Merit 
B, Hu Friedy, Chicago, IL, USA) with a standardized pressure. The distance between the 
marginal border of the mucosa and the tip of the periodontal probe was scored as the 
probing depth. The highest peri-implant scores per patient (plaque-index, gingiva-index and 
calculus) and the highest probing depth per implant were used for analysis.
Radiographic assessments
Marginal bone resorption around the implants was assessed radiographically using 
panoramic radiographs made during the current visit and, when available, from previous 
recordings. On these radiographs, the mesial and distal marginal bone levels were 
determined in relation to the implant shoulder. Marginal bone loss was calculated as the 
difference in peri-implant bone level between the first (i.e., the radiograph at the time the 
suprastructure was placed) and the last radiograph (i.e., the radiograph made during the 
recall visit). The highest scores per implant were used for analysis. In patients in whom no 
radiographs were available from the period the suprastructure was made, the marginal 
bone level was compared to the expected bone level at implant insertion. 
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Table 1. Characteristics of Sjögren’s patients with dental implants and matched healthy controls included 
in this study
          
Sjögren’s patients Healthy controls
Number of patients 50 50
Age (mean±SD, years) 67± 8 66 ± 9
Gender (n, %):
female 46 (92%)  46 (92%)
male 4 (8%) 4 (8%)
SS (n, %):
primary SS (n, %) 41 (82%) NA
secondary SS (n. %) 9 (18%) NA
Disease duration (years, range) 9 (4-14) NA
ESSPRI 6.3 (4.7-7.3) NA
Serological characteristics:
ESR (mm/hour) 22.0 (14.0-40.5) NA
IgG (g/l) 14.4 (11.9-16.3) NA
rheumatoid factor (kIU/L) 26.0 (14.5-116.0) NA
C3 (g/l) 1.1 (1.0-1.2) NA
C4 (g/l) 0.2 (0.1-0.3) NA
anti-Ro/SSA positive (n, %) 41 (82%) NA
anti-La/SSB positive (n, %) 27 (54%) NA
Medication:
NSAIDs ( n, %) 13 (26%) 0 (0%)
corticosteroids (n, %) 8 (16%) 0 (0%)
hydroxychloroquine (n, %) 14 (28%) 0 (0%)
other immunosuppressives (n, %) 5 (10%) 0 (0%)
Smoking (n,%) 1 (2%) 0 (0%)
Dental implants:
maxillary implants (n, %) 20 (14%) 24 (19%)
mandibular implants (n, %) 120 (86%) 101 (81%)
follow-up of implants (years) 3.8 (2.2-6.1) 5.0 (1.0-.0.5)
Implant-retained prosthodontics:
single crown (n) 27 14
overdenture (n) 36 37
fixed partial denture (n) 2 7
fixed full-arch denture (n) 1 0
Variables are presented as medians (IQR) unless stated otherwise; NSAIDs= non-steroidal anti-inflammatory 
drugs; ESSPRI= EULAR Sjögren’s Syndrome Reported Index; NA: not applicable/not assessed
Results
Patients 
In total, 335 of the 406 SS patients responded to the mail survey regarding dental implants 
(response rate 83%). In 21% of these respondents (n= 69) dental implants were inserted. 
These 69 SS patients were invited to the hospital for clinical assessments and completion of 
questionnaires. In 19 patients implant indices could not be assessed as they were currently 
visiting other hospitals because of travelling distance (n=6), they were too ill (n=5) or 
refused to participate (n=8). From 50 patients clinical data could be collected. 
The 50 included patients were a representative sample of the 69 SS patients with 
implants inserted considering no significant differences were found in sex, age and disease 
duration between these 50 patients and the 19 patients without clinical data. Patients’ 
characteristics of the 50 SS patients with dental implants and the 50 matched healthy 
controls are presented in Table 1. 
Peri-implant indices
In total 140 implants were available for clinical assessments in the 50 SS patients (Table 1). 
Peri-implant indices are shown in Table 2. Bleeding index, gingival index and probing depth 
were slightly, though significantly higher in SS patients compared with healthy controls. 
Furthermore, plaque-index and gingiva-index were slightly higher and probing depth was 
slightly lower in edentulous SS patients compared with dentate SS patients, although again 
statistically significant. Peri-implant indices did not differ between patients with pSS or sSS 
and were independent of the use of NSAIDs, corticosteroids, hydroxychloroquine or other 
immunosuppressives. 
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Rotational radiographs (orthopantomograms) at baseline (i.e., around the period the 
suprastructure was made) were available for 26 patients (71 implants), either because the 
implants were inserted in our hospital or radiographs could be obtained from the dentist 
who inserted the implants or made the prosthetic device. Median bone loss around the 
implants in SS patients was 0.89 (0.25-1.56) with a median time between the baseline 
and radiograph made at the recall visit of 42 months (IQR 22-69) (Table 2). There was no 
significant difference in bone loss between SS patients and healthy controls.
Peri-implant mucositis and peri-implantitis
Peri-implant mucositis, defined as bleeding on probing at one or more sites around one 
or more implants, was seen in 94% of the SS patients and in 62% of the healthy controls. 
Peri-implantitis around one or more implants was seen in 14% of the SS patients (11% of the 
implants) and 12% of the healthy controls (Table 2). 
There was no significant difference in the prevalence of peri-implant mucositis and peri-
implantitis between patients with pSS an sSS. Prevalence of peri-implantitis and peri-
implant mucositis were also independent of disease duration and the use of NSAIDs, 
corticosteroids, hydroxychloroquine and other immunosuppressives when in SS patients.
Implant survival
Based on patients’ interview and patients’ records, four out of 142 inserted implants had 
been lost in two patients during the first three months after insertion, resulting in an 
overall survival rate of 97% (median follow up after implant insertion 46 months (IQR 26-
73); Table 2). All four implants had been inserted in the edentulous mandible. Two of these 
four failing implants had been replaced in these patients. These two replaced implants were 
in function for 66 and 36 months at last follow-up, respectively.
In total 125 implants were inserted in the 50 matched healthy controls. No implants were 
lost during a comparable follow-up period (Table 2).
Oral functioning and patients’ symptoms
No significant differences were found in HR-QoL, oral functioning, satisfaction and 
chewing between patients with a fixed superstructure on the implants and patients with a 
prosthesis. Patients’ satisfaction with the prosthetic device was high (Table 2).
OHIP14 scores correlated positively with ESSPRI dryness (ρ=0.393), ESSPRI oral dryness 
(ρ=0.407) and chewing scores (ρ=0.521), and negatively with VAS satisfaction 
(ρ=-0.452). Worse oral functioning was thus associated with more dryness complaints, 
lower patient satisfaction and worse subjective chewing ability. In addition, ESSPRI oral 
dryness correlated positively with chewing score (ρ=0.403) indicating that the dryer the 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Rotational radiographs (orthopantomograms) at baseline (i.e., around the period the 
suprastructure was made) were available for 26 patients (71 implants), either because the 
implants were inserted in our hospital or radiographs could be obtained from the dentist 
who inserted the implants or made the prosthetic device. Median bone loss around the 
implants in SS patients was 0.89 (0.25-1.56) with a median time between the baseline 
and radiograph made at the recall visit of 42 months (IQR 22-69) (Table 2). There was no 
significant difference in bone loss between SS patients and healthy controls.
Peri-implant mucositis and peri-implantitis
Peri-implant mucositis, defined as bleeding on probing at one or more sites around one 
or more implants, was seen in 94% of the SS patients and in 62% of the healthy controls. 
Peri-implantitis around one or more implants was seen in 14% of the SS patients (11% of the 
implants) and 12% of the healthy controls (Table 2). 
There was no significant difference in the prevalence of peri-implant mucositis and peri-
implantitis between patients with pSS an sSS. Prevalence of peri-implantitis and peri-
implant mucositis were also independent of disease duration and the use of NSAIDs, 
corticosteroids, hydroxychloroquine and other immunosuppressives when in SS patients.
Implant survival
Based on patients’ interview and patients’ records, four out of 142 inserted implants had 
been lost in two patients during the first three months after insertion, resulting in an 
overall survival rate of 97% (median follow up after implant insertion 46 months (IQR 26-
73); Table 2). All four implants had been inserted in the edentulous mandible. Two of these 
four failing implants had been replaced in these patients. These two replaced implants were 
in function for 66 and 36 months at last follow-up, respectively.
In total 125 implants were inserted in the 50 matched healthy controls. No implants were 
lost during a comparable follow-up period (Table 2).
Oral functioning and patients’ symptoms
No significant differences were found in HR-QoL, oral functioning, satisfaction and 
chewing between patients with a fixed superstructure on the implants and patients with a 
prosthesis. Patients’ satisfaction with the prosthetic device was high (Table 2).
OHIP14 scores correlated positively with ESSPRI dryness (ρ=0.393), ESSPRI oral dryness 
(ρ=0.407) and chewing scores (ρ=0.521), and negatively with VAS satisfaction 
(ρ=-0.452). Worse oral functioning was thus associated with more dryness complaints, 
lower patient satisfaction and worse subjective chewing ability. In addition, ESSPRI oral 
dryness correlated positively with chewing score (ρ=0.403) indicating that the dryer the 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Some marginal bone loss was observed in our cross-sectional cohort. The median marginal 
bone loss seems to be well within the range that is considered as normal in healthy 
subjects8,9,11,31,32. It has to be mentioned, however, that in our study rotational radiographs 
were used in the evaluation of bone around the implants. This is not optimal, as preferably 
standardized intra-oral dental radiographs are used for evaluation of peri-impant bone loss 
as was used for assessing peri-implant bone loss in our healthy controls. Contrary to our 
results, in one small study it was suggested that marginal peri-implant bone loss was higher 
in sSS patients compared with patients with RA without sSS19. This topic needs further 
study, but it seems that the difference between healthy patients and SS patients has limited 
clinical relevance as the prevalence of peri-implantitis showed no difference between the 
two groups. 
Overall implant survival in this cohort was 97% with a median follow-up of 46 months, 
which is comparable to the implant survival in our matched healthy controls and the 
previously reported implant survival in healthy patients8-11. All 4 lost implants were lost 
within 3 months after insertion, comparable with the timing of implant loss in healthy 
patients8-11. In two other studies on implant survival in SS patients reported in literature, 
implant survival in SS patients was 84% and 100%, respectively16,19.
The findings of the oral functioning questionnaires in our study are consistent with the 
results from previous studies in SS patients2,4,5,38. Oral functioning is impaired in patients 
with SS and continues to be impaired in patients with implant-retained prosthetics. 
Subjective chewing ability with implant-based prosthetics did not reach the same level 
as reported for healthy subjects7. SS patients with implant-retained prosthetics report 
difficulty chewing tough and hard food, although there is a large variety in results. These 
problems can be due to the sicca component of SS, as shown by the direct correlation 
between severity of reported oral dryness (ESSPRI dryness) and chewing ability. This could 
also explain why SS patients were less satisfied with their implant-retained prosthetics than 
non-SS patients. 
Based on the present analysis, we conclude that dental implants are a good treatment 
option in the prosthetic treatment of patients with SS, although there are more signs of 
peri-implant mucositis in SS subjects than in healthy controls. Implant survival is high, 
prevalence of peri-implantitis is comparable to healthy patients, no excessive bone loss 
was seen and patients were satisfied with their implant-retained prosthetic devices. 
Dentist, implantologists, rheumatologist and other health care workers should encourage 
SS patients with dental problems to discuss the possibilities to treat dental problems with 
implant-retained prosthetics. 
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Discussion
To the best of our knowledge, this is the first study on the prevalence of the use of dental 
implants, peri-implant health, prevalence of peri-implant mucositis and peri-implantitis, 
implant survival as well as HR-QoL and oral functioning in a large cohort of well-classified 
patients with SS. Major findings are the high percentage of patients with implants installed, 
the rather good peri-implant health not withstanding the high prevalence of peri-implant 
mucositis, the limited prevalence of peri-implantitis, the high implant survival (97%) and the 
high satisfaction of patients with their implant-retained prosthetic rehabilitation. 
In 21% of the respondents implants had been inserted. In the Netherlands in 2009, 8.0% 
of the population between 60-70 and 7.0% of the population of 70 years and older had 
implants inserted (Statistics Netherlands, www.cbs.nl). Apparently, there is a large demand 
for inserting implants in patients with SS, but not much is known whether this treatment 
is successful or not. This large demand can be explained by the early loss of teeth in 
patients with SS and the inability to wear (partial) dentures because of the dry, sensitive 
oral mucosa. Moreover, to our experience, SS patients have a rather high dental awareness 
and are thus more demanding regarding optimal dental care including insertion of dental 
implants to solve dental problems. 
SS patients had more signs of soft tissue infection compared with the healthy controls. 
Care must be undertaken when interpreting these results. The healthy controls were 
obtained from previous prospective randomized trials, with long follow-up. In SS patients 
the implants had been inserted in routine dental care settings by several dentists and oral 
surgeons reflecting common dental care in the Netherlands. As a result, not all SS patients 
had been subjected to strict, standardized follow-up and oral hygiene measures as usually 
is the case in well controlled clinical studies. Furthermore, salivary secretion is reduced 
in SS patients as well as the related self- clearance of the oral cavity. As a result, debris 
will collect more quickly and remain on the implant surfaces in SS subjects than in healthy 
controls. This is reflected by the slightly higher gingival health indices and pocket probing 
depth values in our SS subjects than in their matched controls. As a result the marginal 
peri-implant tissue is more prone to continuous inflammatory insults than the peri-implant 
tissue in healthy controls. This will probably have resulted in more gingival swelling, 
bleeding and increased pocket probing depths in SS patients.
Although probably not clinically relevant as the observed differences were on the healthy 
end of the peri-implant health spectrum, peri-implant mucosa was healthier for dentate 
SS patients compared with edentulous SS patients. Dentate SS patients need to have 
better oral hygiene compared with edentulous patients as their natural teeth are prone to 
decay as they are exposed to an oral environment with a high risk of dental caries and oral 
infections. This better oral hygiene need is reflected in a lower gingiva-index and plaque-
index. Remarkably, a comparable difference has also been observed in healthy patients 
supplied with removable or fixed implant-based prosthodontics37. 
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Chapter 6
General discussion
